Last reviewed · How we verify
NCT04689204
A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies
EARLY_PHASE1 trial testing CTA30X in Acute Lymphoblastic Leukemia in 3 participants. Completed in 31 May 2024.
29 December 2022
Quick facts
| Lead sponsor | He Huang |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 3 |
| Start date | 29 December 2020 |
| Primary completion | 29 December 2022 |
| Estimated completion | 31 May 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- CTA30X — full drug profile →
Conditions studied
- Acute Lymphoblastic Leukemia — all drugs for Acute Lymphoblastic Leukemia →
- Non-hodgkin Lymphoma — all drugs for Non-hodgkin Lymphoma →
Sponsor
He Huang — full company profile →
Who can join
Adults 3 to 70, any sex, with Acute Lymphoblastic Leukemia or Non-hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A study of CTA30X cell injection in the treatment of relapsed or refractory CD19-positive B-line hematological malignancies
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04689204
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Lymphoblastic Leukemia
Currently open trials in the same condition.
- NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT05621291 — A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Follo · NA · recruiting
- NCT07356154 — A Study of Revumenib and Mezigdomide in People With Leukemia · Phase 1, PHASE2 · recruiting
- NCT07479927 — Telematic Cognitive Training and Mindfulness in Pediatric Patients After CAR-T Cell Therapy, Single Hematopoietic Alloge · NA · recruiting
Other He Huang trials
Trials by the same sponsor.
- NCT06887985 — JY231(JY231) Injection for the Treatment of Refractory Autoimmune Diseases (ADs) · NA · not yet recruiting
- NCT06902025 — JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia · NA · not yet recruiting
- NCT06785519 — CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis · EARLY_PHASE1 · recruiting
- NCT06709131 — A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia · Phase 1 · suspended
- NCT06571825 — RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04689204 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by He Huang
- Last refreshed: 24 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04689204.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing